HI-511 overcomes melanoma drug resistance

Autor: Xiaoyu, Chang, Tianshun, Zhang, Qiushi, Wang, Moeez Ghani, Rathore, Kanamata, Reddy, Hanyong, Chen, Seung Ho, Shin, Wei-Ya, Ma, Ann M, Bode, Zigang, Dong

Publikováno v: Theranostics

Rationale: Melanoma is an aggressive tumor of the skin and drug resistance is still a major problem in melanoma therapy. Novel targets and effective agents to overcome drug resistant melanoma are urgently needed in clinical therapy. Methods: Gene Exp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::60abe331dd0c9985b18e0f659bfa0ffe
https://pubmed.ncbi.nlm.nih.gov/32863956

BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers.

Autor: Castellani, Giorgia¹ (AUTHOR) giorgia.castellani@iss.it, Buccarelli, Mariachiara¹ (AUTHOR) mariachiara.buccarelli@iss.it, Arasi, Maria Beatrice¹ (AUTHOR) mariabeatrice.arasi@iss.it, Rossi, Stefania¹ (AUTHOR) stefania.rossi@iss.it, Pisanu, Maria Elena² (AUTHOR) mariaelena.pisanu@iss.it, Bellenghi, Maria³ (AUTHOR) maria.bellenghi@iss.it, Lintas, Carla^4,5 (AUTHOR) clintas@unicampus.it, Tabolacci, Claudio¹ (AUTHOR) claudio.tabolacci@iss.it

Publikováno v: Cancers. Aug2023, Vol. 15 Issue 16, p4026. 30p.

AURKB targets DHX9 to promote hepatocellular carcinoma progression via PI3K/AKT/mTOR pathway.

Autor: Zhu G; Department of General Surgery, The First Hospital of Nanchang, The Third Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China.; Department of General Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China., Luo L; Department of General Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China., He Y; Department of General Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China.; Department of General Surgery, Division of Hepatobiliary and Pancreas Surgery, Shenzhen People's Hospital, The Second Clinical Medical College, Jinan University, Shenzhen, Guangdong Province, China.; The First Affiliated Hospital, Southern University of Science and Technology, Shenzhen, Guangdong Province, China., Xiao Y; Department of General Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China., Cai Z; Department of General Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China., Tong W; Department of Orthopedics, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China., Deng W; Department of General Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China., Xie J; Department of General Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China., Zhong Y; Department of Orthopedics, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China., Hu Z; Department of General Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China., Shan R; Department of General Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China.

Publikováno v: Molecular carcinogenesis [Mol Carcinog] 2024 Sep; Vol. 63 (9), pp. 1814-1826. Date of Electronic Publication: 2024 Jun 14.

Identification of a distinct tumor endothelial cell-related gene expression signature associated with patient prognosis and immunotherapy response in multiple cancers.

Autor: Zhuo X; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.; Department of Otolaryngology, Head and Neck Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China., Huang C; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.; Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China., Su L; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.; Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China., Liang F; Department of Otolaryngology, Head and Neck Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China., Xie W; Department of Otolaryngology, Head and Neck Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China., Xu Q; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.; Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China., Han P; Department of Otolaryngology, Head and Neck Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China., Huang X; Department of Otolaryngology, Head and Neck Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. hxming@mail.sysu.edu.cn., Wong PP; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. huangbp3@mail.sysu.edu.cn.; Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. huangbp3@mail.sysu.edu.cn.

Publikováno v: Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2023 Sep; Vol. 149 (12), pp. 9635-9655. Date of Electronic Publication: 2023 May 25.

Stereochemistry of halopyridyl and thiazolyl thiourea compounds is a major determinant of their potency as nonnucleoside inhibitors of HIV-1 reverse transcriptase

Autor: Fatih M. Uckun, Taracad K. Venkatachalam, Chen Mao, Elise A. Sudbeck

Publikováno v: Bioorganic & Medicinal Chemistry Letters. 10:2071-2074

Chiral derivatives of two cyclohexylethyl halopyridyl thiourea compounds (HI-509 and HI-510), two α-methyl benzyl halopyridyl compounds (HI-511 and HI-512), and a cyclohexyl ethyl thiazolyl thiourea compound (HI-513) were synthesized as nonnucleosid

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae1284d4d6b9481c907f9f8f7029d223
https://doi.org/10.1016/s0960-894x(00)00398-x